Bimatoprost

Basic bimatoprost information

• INN (international nonproprietary name): Bimatoprost.
• Brand names available in the United Kingdom: Lumigan (ophthalmic solution).
• ATC code: S01EE03 (Prostaglandin analogue for reduction of elevated intraocular pressure).
• Forms & dosages: Eye drops 0.01% and 0.03% (0.1 mg/mL and 0.3 mg/mL) in 2.5–7.5 mL droppers; intracameral implant Durysta 10 mcg.
• Manufacturers in the United Kingdom: Licensed product Lumigan (Allergan / AbbVie) with generics supplied by companies such as Brown & Burk UK, Sandoz and others.
• Registration status in the United Kingdom: Authorised by the MHRA; Lumigan is registered for glaucoma and ocular hypertension.
• OTC / Rx classification: Prescription only (Rx) — bimatoprost is not available over the counter.

Clinical effectiveness in the United Kingdom

How well does bimatoprost work in practice?

Bimatoprost is well established in UK ophthalmology pathways for open‑angle glaucoma and ocular hypertension, commonly used as part of first‑ or second‑line treatment depending on local formularies and clinical assessment.

Standard once‑daily evening administration gives effective IOP lowering, and adherence improves when pharmacists and glaucoma nurses provide instillation technique training.

Forms and strengths used in the UK include Lumigan eye drops at 0.1 mg/mL and 0.3 mg/mL (0.01% and 0.03%) and intracameral implant options such as Durysta for selected patients.

Clinicians often choose bimatoprost when target pressure requires maximal prostaglandin effect or when patients welcome eyelash benefit, but increased hyperaemia may prompt therapy change.

Common adverse reactions:

• Conjunctival hyperaemia (red eyes).
• Eyelash growth and darkening.
• Periorbital skin pigmentation and occasional blurred vision.

Indications and expanded uses (MHRA and common off‑label)

Patients frequently ask whether bimatoprost is only for glaucoma or if it has cosmetic uses.

The licensed indication in the UK is the reduction of elevated intraocular pressure in open‑angle glaucoma or ocular hypertension is the primary therapeutic licence for Lumigan.

The intracameral implant Durysta has its own indication and administration route for selected glaucoma patients.

Off‑label use occurs occasionally in specialist NHS centres for refractory glaucoma cases where individual patient risk–benefit assessment supports alternative approaches.

Contraindications and monitoring requirements restrict use in aphakic or pseudophakic eyes with a torn posterior capsule and in the presence of active intraocular inflammation.

Definitions:

• Licensed: approved indication and marketing authorisation from regulator for specified use.
• Off‑label: a use supported by clinician judgement but not covered by the product licence.
• Cosmetic vs therapeutic: cosmetic use aims at appearance (eyelash growth) while therapeutic use aims to reduce IOP and prevent glaucomatous damage.

Licence overview:

Composition and brand landscape

Which brands and formulations are available in the UK?

The active ingredient is bimatoprost (INN), a prostaglandin analogue classified under ATC S01EE03 and used in both ophthalmic and cosmetic products.

Lumigan is the principal licensed brand available in the United Kingdom in 0.1 mg/mL and 0.3 mg/mL ophthalmic solutions (0.01% and 0.03%).

Durysta is the 10 mcg intracameral implant provided as a sterile single‑use device.

Generic bimatoprost is made by manufacturers such as Alembic, Apotex, Gland Pharma, Micro Labs, Sandoz and Brown & Burk UK.

Packaging typically includes 2.5–7.5 mL dropper bottles for eye drops, single‑use vials and sterile single‑use implant devices for Durysta.

Brand summary:

Contraindications and special precautions

Which patients should not use bimatoprost or require extra monitoring?

Absolute contraindications include known hypersensitivity to bimatoprost or any excipient, active intraocular inflammation such as uveitis or iritis, and eyes with aphakia or pseudophakia with a torn lens capsule due to macular oedema risk.

Relative precautions apply to patients with a history of herpetic keratitis, severe respiratory disease, significant liver or kidney impairment and those who are pregnant or breastfeeding.

Practical daily‑life restrictions include the possibility of transient blurred vision after instillation that may affect driving and the need to avoid driving until vision clears.

Contact‑lens wearers should remove lenses before instillation and reinsert after approximately 15 minutes to avoid preservative absorption into the lens.

Recommended screening and monitoring:

• A pre‑treatment check for posterior capsule integrity in pseudophakic patients.
• Routine IOP monitoring as part of glaucoma care.
• Prompt review if there are signs of macular oedema, persistent uveitis or severe ocular discomfort.

Macular oedema risk: rare but more likely in aphakic/pseudophakic eyes with torn posterior capsule or in patients with risk factors for macular changes.

Dosage guidelines (NHS recommended regimens)

How should patients use bimatoprost safely and effectively?

Standard ophthalmic dosing is one drop in the affected eye or eyes once daily in the evening, and dosing must not exceed once daily.

Ophthalmic strengths commonly used in the UK are recorded as 0.01% and 0.03% (0.1 mg/mL and 0.3 mg/mL respectively).

For eyelash hypotrichosis the topical cosmetic regimen is 0.03% solution applied once daily to the upper eyelid margin in the evening.

The Durysta intracameral implant is a one‑time 10 mcg administration for selected glaucoma patients under specialist care.

Special populations:

• Children: not recommended due to unestablished safety and efficacy.
• Elderly: no routine dose adjustment, but closer monitoring advised in significant renal impairment.
• Liver or kidney impairment: use with caution and monitor for increased adverse effects.

Missed dose: administer when remembered unless it is near the time for the next dose and do not double up.

Interactions overview and pharmacovigilance

What are the important interaction and reporting points clinicians and patients should know?

Systemic drug interactions are uncommon with topical bimatoprost because systemic exposure is low, but care should be taken when combining multiple ocular hypotensive agents.

Combining two prostaglandin analogues is generally unnecessary; where combination therapy is used, formulations with separate agents such as timolol may be preferred.

MHRA Yellow Card reporting channels should be used to capture suspected adverse reactions, including the common signals of conjunctival hyperaemia and eyelash changes and rarer reports of macular oedema and uveitis in at‑risk patients.

There are no clinically significant food or drink interactions, and specific alcohol or caffeine restrictions are not required.

Interaction checklist:

• Do not presume benefit from adding another prostaglandin analogue; consult ophthalmology if pressure control is inadequate.
• Monitor closely if switching from or to combination agents containing timolol due to systemic beta‑blocker considerations.
• Report all unexpected ocular inflammation, visual changes or severe irritation promptly via Yellow Card and to the treating clinician.

The most commonly reported reactions include hyperaemia, eyelash growth and pigmentation changes, with rare reports of macular oedema in predisposed eyes.

Legal status and availability in the UK

Bimatoprost is a prescription‑only medicine (POM) in the UK.

In our online pharmacy, bimatoprost is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Comparable medicines and prescribing preferences

Patients often ask why one prostaglandin analogue is chosen over another.

Alternatives on NHS formularies include latanoprost, travoprost, tafluprost, all prostaglandin analogues used to reduce IOP.

Efficacy across the class is broadly similar, but individual response and tolerability differ which drives personalised prescribing.

Clinicians may prefer bimatoprost when a maximal prostaglandin effect is required or when patients welcome eyelash benefit, while switching agents can address side effects such as persistent conjunctival hyperaemia or periorbital pigmentation.

Local formulary guidance influences first‑line choices.

Pros and cons:

• Pros: strong IOP lowering, eyelash benefit where desired, established evidence base.
• Cons: higher incidence of hyperaemia and pigmentation in some patients, rare macular oedema risk in susceptible eyes.
• Practical consideration: check local NHS formulary for preferred first‑line agents and discuss tolerability preferences with the patient.

Frequently asked questions

Will bimatoprost change my eye colour?

Iris darkening has been reported with prostaglandin analogues and is more likely after prolonged unilateral use; discuss monitoring with your ophthalmologist.

Can I wear contact lenses after using the drops?

Remove contact lenses before instillation and reinsert after about 15 minutes to avoid preservative uptake into the lens.

Is eyelash growth permanent?

Cosmetic eyelash effects reverse after discontinuation and sustained use is required to maintain the effect.

How do I report side effects?

Report adverse effects to your prescriber, pharmacist or via the MHRA Yellow Card scheme.

Guidelines for proper use and pharmacist counselling

What should pharmacists and clinic staff tell patients at the point of supply?

Verify indication and pregnancy status before supply and confirm the prescribed strength and administration route.

Demonstrate instillation technique: tilt head back, pull lower lid down to form a pocket, instil one drop, close the eye for 1–2 minutes and perform nasolacrimal occlusion for one minute to reduce systemic absorption.

Advise evening dosing only once per day and to wait at least five minutes between different eye drops when multiple topical agents are used.

Warn patients about common local effects such as conjunctival hyperaemia, eyelash changes and periocular pigmentation and instruct on contact‑lens removal before application.

Storage advice: keep in the original packaging between 2–25°C, do not freeze and discard after the recommended in‑use period (typically 28 days once opened).

Provide printed leaflets, signpost to accredited resources and encourage Yellow Card reporting for suspected adverse reactions.

Step-by-step instillation:

1. Wash hands before handling the bottle.
2. Remove contact lenses if worn and wait 15 minutes after application to reinsert.
3. Instil one drop into the lower conjunctival sac once daily in the evening.
4. Close the eye and press gently on the inner corner for one minute.
5. Replace cap without touching the dropper tip and store as directed.

Delivery across the United Kingdom